Cancer Therapy: Clinical Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia


Purpose:Chronic lymphocytic leukemia (CLL) cells treatedwith dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the activity of dasatinib in patients with relapsed CLL. Experimental Design: Patients were eligible for this phase II trial if they had documented CLL/SLL and had failed at least 1 prior therapy with… (More)


6 Figures and Tables